{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumors (RECIST) for target lesions assessed by CT or MRI: Complete Response (CR) is the disappearance of all target lesions (TL) and non-target lesions (NTL); Partial Response (PR) is defined by either a CR of TL and stable disease (SD) in NTL or PR of TL and non-progressive disease (PD) in NTL. Response rate is the sum of CR + PR as defined above.","groups":[{"description":"doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.\n\ngemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle","id":"OG000","title":"Gemcitabine+Doxorubicin"}],"paramType":"NUMBER","populationDescription":"patients who were on study at the time of response assessment","reportingStatus":"POSTED","timeFrame":"Every 6 weeks from the time of initial treatment for up to 8 months","title":"Response Rate","type":"PRIMARY","unitOfMeasure":"participants"}